Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micrus Endovascular enters Japan

This article was originally published in The Gray Sheet

Executive Summary

Japan's Ministry of Health, Labor & Welfare (MHLW) clears firm to sell MicruSphere, HeliPaq and InterPaq embolic coils to treat cerebral aneurysms. The firm hopes to convert the Japanese market from craniotomy - used on 75% of aneurysms - to coiling. According to Micrus, nearly one third of all interventional cerebral vascular disease treatment revenue comes from Japan. Following the clearance, the firm announced that it would work with Japanese distributor Goodman to clear further products in Japan, including the Cerecyte microcoil. The firm also plans to enter the Chinese market by June. One year ago, the firm noted that it would use proceeds from its $57.5 mil. initial public offering to break in to the Japanese market (1"The Gray Sheet" March 14, 2005, p. 31)...
Advertisement

Related Content

Micrus IPO To Fund Japan Aneurysm Coil Market Entry, Bioactive Coil R&D
Micrus IPO To Fund Japan Aneurysm Coil Market Entry, Bioactive Coil R&D
Advertisement
UsernamePublicRestriction

Register

MT023318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel